SEGMENTAL OVERGROWTH DISORDERS DUE TO PIK3CA

Clinical trials for SEGMENTAL OVERGROWTH DISORDERS DUE TO PIK3CA explained in plain language.

Never miss a new study

Get alerted when new SEGMENTAL OVERGROWTH DISORDERS DUE TO PIK3CA trials appear

Sign up with your email to follow new studies for SEGMENTAL OVERGROWTH DISORDERS DUE TO PIK3CA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

Drug trial targets rare genetic overgrowth disorder

Disease control Completed

This study tested whether the drug sirolimus could stop the progression of abnormal, excessive growth in specific body parts of people with a genetic condition called PIK3CA-related overgrowth. Sixteen participants, aged 3 to 65, took sirolimus for six months after a six-month mo…

Matched conditions: SEGMENTAL OVERGROWTH DISORDERS DUE TO PIK3CA

Phase: PHASE2 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control

Last updated Mar 18, 2026 14:55 UTC

SEGMENTAL OVERGROWTH DISORDERS DUE TO PIK3CA

Get alerted when new SEGMENTAL OVERGROWTH DISORDERS DUE TO PIK3CA trials appear

Drug trial targets rare genetic overgrowth disorder